Literature DB >> 28559262

Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.

Noton K Dutta1, Michael L Pinn1, Petros C Karakousis2,3.   

Abstract

Preliminary preclinical and observational studies suggest the potential utility of metformin as an adjunctive, host-directed agent for treatment of tuberculosis (TB). In this study, we sought to investigate the bactericidal and sterilizing activities of human-like exposures of metformin when given in combination with the first-line regimen against chronic tuberculosis in BALB/c mice. Mice receiving metformin adjunctive therapy had similar lung bacillary burdens with control mice during treatment, and the proportion of mice with microbiological relapse was similar between the two groups.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  BALB/c; Denver regimen; Mycobacterium tuberculosis; bactericidal; cure; host-directed therapy; metformin; relapse; standard first-line regimen; sterilizing

Mesh：

Substances：

Year:  2017        PMID： 28559262      PMCID： PMC5527622          DOI： 10.1128/AAC.00652-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.

Authors:  D L Cohn; B J Catlin; K L Peterson; F N Judson; J A Sbarbaro
Journal:  Ann Intern Med       Date:  1990-03-15       Impact factor: 25.391

2.  Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol.

Authors:  Lindsey H M Te Brake; Jeroen J M W van den Heuvel; Aaron O Buaben; Reinout van Crevel; Albert Bilos; Frans G Russel; Rob E Aarnoutse; Jan B Koenderink
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

3.  Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.

Authors:  Noton K Dutta; Michael L Pinn; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

4.  Metformin as adjunct antituberculosis therapy.

Authors:  Amit Singhal; Liu Jie; Pavanish Kumar; Gan Suay Hong; Melvin Khee-Shing Leow; Bhairav Paleja; Liana Tsenova; Natalia Kurepina; Jinmiao Chen; Francesca Zolezzi; Barry Kreiswirth; Michael Poidinger; Cynthia Chee; Gilla Kaplan; Yee Tang Wang; Gennaro De Libero
Journal:  Sci Transl Med       Date:  2014-11-19       Impact factor: 17.956

5.  Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.

Authors:  Noton K Dutta; Michael L Pinn; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

6.  Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.

Authors:  Zahoor Ahmad; Eric L Nuermberger; Rokeya Tasneen; Michael L Pinn; Kathy N Williams; Charles A Peloquin; Jacques H Grosset; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2010-01-31       Impact factor: 5.790

7.  Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.

Authors:  J Dhillon; J M Dickinson; K Sole; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

9.  Metformin ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice.

Authors:  Guoshun Xu; Hongying Wu; Junling Zhang; Deguan Li; Yueying Wang; Yingying Wang; Heng Zhang; Lu Lu; Chengcheng Li; Song Huang; Yonghua Xing; Daohong Zhou; Aimin Meng
Journal:  Free Radic Biol Med       Date:  2015-06-16       Impact factor: 7.376

10.  Protective effect of metformin against tuberculosis infections in diabetic patients: an observational study of south Indian tertiary healthcare facility.

Authors:  Srujitha Marupuru; Padmanav Senapati; Swathi Pathadka; Sonal Sekhar Miraj; Mazhuvancherry Kesavan Unnikrishnan; Mohan K Manu
Journal:  Braz J Infect Dis       Date:  2017-02-13       Impact factor: 3.257
View more
  20 in total

Review 1.  Remembering the Host in Tuberculosis Drug Development.

Authors:  Daniel J Frank; David J Horne; Noton K Dutta; Moagi Tube Shaku; Rajhmun Madensein; Thomas R Hawn; Adrie J C Steyn; Petros C Karakousis; Bavesh Davandra Kana; Graeme Meintjes; Barbara Laughon; Zaid Tanvir
Journal:  J Infect Dis       Date:  2019-04-19       Impact factor: 5.226

2.  Disparate Effects of Metformin on Mycobacterium tuberculosis Infection in Diabetic and Nondiabetic Mice.

Authors:  Harindra D Sathkumara; Karyna Hansen; Socorro Miranda-Hernandez; Brenda Govan; Catherine M Rush; Lars Henning; Natkunam Ketheesan; Andreas Kupz
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

3.  Potentiation of rifampin activity in a mouse model of tuberculosis by activation of host transcription factor EB.

Authors:  Ruslana Bryk; Shashirekha Mundhra; Xiuju Jiang; Madeleine Wood; Daniel Pfau; Elaina Weber; Suna Park; Li Zhang; Colin Wilson; Renier Van der Westhuyzen; Leslie Street; Kelly Chibale; Matthew Zimmerman; Véronique Dartois; Nunzia Pastore; Andrea Ballabio; Natalie Hawryluk; Stacie Canan; Vikram Khetani; Joseph Camardo; Carl Nathan
Journal:  PLoS Pathog       Date:  2020-06-23       Impact factor: 6.823

4.  A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin.

Authors:  Jamie N Justice; Sriram Gubbi; Ameya S Kulkarni; Jenna M Bartley; George A Kuchel; Nir Barzilai
Journal:  Geroscience       Date:  2020-09-09       Impact factor: 7.713

5.  Metformin Alters Human Host Responses to Mycobacterium tuberculosis in Healthy Subjects.

Authors:  Ekta Lachmandas; Clare Eckold; Julia Böhme; Valerie A C M Koeken; Mardiana Binte Marzuki; Bastiaan Blok; Rob J W Arts; Jinmiao Chen; Karen W W Teng; Jacqueline Ratter; Elise J Smolders; Corina Van den Heuvel; Rinke Stienstra; Hazel M Dockrell; Evan Newell; Mihai G Netea; Amit Singhal; Jacqueline M Cliff; Reinout Van Crevel
Journal:  J Infect Dis       Date:  2019-06-05       Impact factor: 5.226

Review 6.  Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.

Authors:  Rodrigo Abreu; Pramod Giri; Fred Quinn
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

Review 7.  Metformin as Host-Directed Therapy for TB Treatment: Scoping Review.

Authors:  Nikita Naicker; Alex Sigal; Kogieleum Naidoo
Journal:  Front Microbiol       Date:  2020-04-29       Impact factor: 5.640

8.  Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: A nationwide cohort study with validated diagnostic criteria.

Authors:  Ming-Chia Lee; Chen-Yuan Chiang; Chih-Hsin Lee; Cheng-Maw Ho; Chia-Hao Chang; Jann-Yuan Wang; Shih-Ming Chen
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

9.  Metformin Decreases Risk of Tuberculosis Infection in Type 2 Diabetes Patients.

Authors:  Chin-Hsiao Tseng
Journal:  J Clin Med       Date:  2018-09-09       Impact factor: 4.241

Review 10.  Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?

Authors:  Hyun-Eui Park; Wonsik Lee; Min-Kyoung Shin; Sung Jae Shin
Journal:  Front Immunol       Date:  2021-06-28       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.